Abstract
Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
CNS & Neurological Disorders - Drug Targets
Title:Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease
Volume: 15 Issue: 3
Author(s): Juan C. Jurado-Coronel, Marco Ávila-Rodriguez, Valentina Echeverria, Oscar Alejandro Hidalgo, Janneth Gonzalez, Gjumrakch Aliev and George E. Barreto
Affiliation:
Abstract: Green tea is a beverage consumed around the world that is believed to have substantial health benefits such as reducing the risk of cancer, cardiovascular diseases, diabetes and neurodegeneration. This beverage is prepared from the leaves (steamed and dried) of the Camellia sinesis plant and contains strong antioxidant and neuroprotective phenolic compounds from which the most important is (-)-Epigallocatechin-3-gallate. Parkinson’s disease (PD) is the second more common neurodegenerative disorders, after Alzheimer’s disease and is characterized by degeneration of dopaminergic neurons in the pars compact of the substantia nigra of the basal ganglia. It has been shown in pre-clinical and clinical studies that green tea may be able to prevent PD, but its optimal dose or a possible mechanism explaining its health benefit in PD has not been properly established. In this review, we discuss the potential role of green tea’s phenolic compounds and their therapeutic effectin modulating key signaling pathways in the PD brain.
Export Options
About this article
Cite this article as:
Jurado-Coronel C. Juan, Ávila-Rodriguez Marco, Echeverria Valentina, Hidalgo Alejandro Oscar, Gonzalez Janneth, Aliev Gjumrakch and Barreto E. George, Implication of Green Tea as a Possible Therapeutic Approach for Parkinson Disease , CNS & Neurological Disorders - Drug Targets 2016; 15 (3) . https://dx.doi.org/10.2174/1871527315666160202125519
DOI https://dx.doi.org/10.2174/1871527315666160202125519 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Opioid Growth Factor and its Derivatives as Potential Non-toxic Multifunctional Anticancer and Analgesic Compounds
Current Medicinal Chemistry Curcumin and Curcumin-like Molecules: From Spice to Drugs
Current Medicinal Chemistry Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets The Underestimated Role of Mechanical Stimuli in Brain Diseases and the Relate d In Vitro Models
Current Pharmaceutical Design Small-molecule Inhibitors of Epigenetic Mutations as Compelling Drugtargets for Myelodysplastic Syndromes
Current Cancer Drug Targets Looking at Drug Resistance Mechanisms for Microtubule Interacting Drugs: Does TUBB3 Work?
Current Cancer Drug Targets Anti-Angiogenic Therapy as a Cancer Treatment Paradigm
Current Medicinal Chemistry - Anti-Cancer Agents Overcoming the Hurdles of Tumor Immunity by Targeting Regulatory Pathways in Innate and Adaptive Immune Cells
Current Pharmaceutical Design Papillary Thyroid Carcinoma in Pediatric Age: An Example of a Rare Tumour Managed Within a Cooperative Comprehensive Project
Current Pediatric Reviews Using Cell Cultures for the Investigation of Treatments for Attention Deficit Hyperactivity Disorder: A Systematic Review
Current Neuropharmacology Re and Tc Complexes with Pyrazolyl-Containing Chelators: from Coordination Chemistry to Target-Specific Delivery of Radioactivity
Current Radiopharmaceuticals Mitochondria as Therapeutic Targets of Estrogen Action in the Central Nervous System
Current Drug Targets - CNS & Neurological Disorders Potential Medications or Compounds Acting on Toll-like Receptors in Cerebral Ischemia
Current Neuropharmacology Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention
Current Pharmaceutical Design Efficacy of Ropinirole-Loaded PLGA Microspheres for the Reversion of Rotenone- Induced Parkinsonism
Current Pharmaceutical Design Antipsychotics as Psychosis Drugs and Neuroprotective Promoters Evaluated by Chemical QSAR - in silico and in vivo Studies
Letters in Drug Design & Discovery A Systemic Approach to Cancer Treatment: Tumor Cell Reprogramming Focused on Endocrine-Related Cancers
Current Medicinal Chemistry Secondary Neoplasms in Children Treated for Cancer
Current Pediatric Reviews The Many Faces of Aβ: Structures and Activity
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents